Sector: Life Sciences

Latest content

Patent Term Adjustment in Brazil at the centre of major battle for IP owners

Almost 50 cases have arisen in which IP owners are asserting their rights to an extended timeframe, the outcomes of which will have major ramifications in Latin America’s largest economy

30 May 2023

Ravgen assertion campaign highlights problems with US patent reforms

The diagnostics innovator has bagged a further $100 million in damages, but the country’s patent system has put unnecessary hurdles in the way, argues representative John Desmarais.

25 May 2023

Diabetes drug ruling attempts to provide clarity amid pharma enforcement struggle

Pharma companies in India are struggling to enforce compounds that are covered by both genus and subsequent species patents. While the latest case involved a series of injunctions being vacated, the patent community is still unsatisfied by the lack of concrete judgments on this issue.

24 May 2023

US Sanofi-Aventis precedent adds to toolbox for patentee prosecution and litigation success

The ruling by the US Court of Appeals for the Federal Circuit limits analogous art, and innovators can leverage this precedent by adopting certain patent drafting methods

23 May 2023

Five key takeaways from SCOTUS’ landmark Amgen v Sanofi enablement ruling

The Supreme Court yesterday handed down one of the most anticipated patent decisions in decades

19 May 2023

UPC central division will have branch in Milan, Italian government announces

But there’s no clarity yet on the new section’s competencies

19 May 2023

German court issues first ever AASI in life sciences case

The Munich Regional Court has also granted a permanent injunction against NanoString Technologies

18 May 2023

SCOTUS turns down much-watched ‘skinny label’ appeal in blow to generic drug companies

The decision, leaving in place a polarising Federal Circuit decision, has significant implications for life sciences IP strategies

16 May 2023

It is time for life sciences IP professionals to embrace change in the industry

Opinion: Pharma and biotech patent professionals must adapt to new challenges and opportunities

13 May 2023

Biogen’s European exclusivity boost is silver lining following US Tecfidera disaster

Following a catastrophic loss of exclusivity stateside, the company has received a boost in the EU

12 May 2023

Unlock unlimited access to all IAM content